Gianluca Mauri

Also affiliated with Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, IFOM

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors”.

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1850

N/A

0DataRank · unranked

1 citations

T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes +13 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0DataRank · unranked

36 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more